Which Path Will Spectrum Pharmaceuticals Take?

On Monday, Spectrum Pharmaceuticals (Nasdaq: SPPI  ) asked its shareholders to increase the number of authorized shares from 100 million to 175 million, and the shareholders agreed. Two days later, the company announced that the board of directors authorized the repurchase of $25 million in shares.

Confused?

The simple explanation is that the authorizations don't require the company to do anything -- Spectrum doesn't have to sell more shares just because it has them, nor does it have to buy back shares just because the board authorized it to do so.

But the authorizations are still polar opposites. Which way will Spectrum head? It probably depends on what opportunities come Spectrum's way.

The company doesn't need to raise any cash to fund daily operations and current research-and-development programs, so the default path is to buy back shares assuming the company is cash-flow-positive. The authorization is only about 5% of the outstanding shares, and some of the repurchased shares will just cancel out shares issued for warrants and employee options.

Alternatively, if something interesting comes along, the authorized shares give Spectrum the ability to use its shares to buy or license a new product. The company's mode of operation is to look for new compounds outside its walls. Spectrum entered into a joint venture with Cell Therapeutics (Nasdaq: CTIC  ) to sell Zevalin, which Biogen Idec (Nasdaq: BIIB  ) originally developed, and eventually acquired all the rights to the cancer drug. Its other marketed product, Fusilev, was acquired from Targent.

In that regard, Spectrum is a lot like PDL Biopharma (Nasdaq: PDLI  ) . Investors will need to trust management to invest their equity wisely -- be it through share repurchases or acquisitions. If the uncertainty keeps you up at night, perhaps it's best to pass on Spectrum.

Interested in small companies? Grab this free report from Motley Fool analysts: "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke."

Want to know the latest drug stock we've picked for the Fool's market-beating Rule Breakers newsletter service? Check out all our recommendations with a free 30-day trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool's disclosure policy is still confused about the birds and the bees.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 17, 2011, at 10:17 AM, HalDaniels wrote:

    I own shares of this stock (SPPI). I don't remember anyone asking me for permission to issue an additional 75 million shares.??

Add your comment.

DocumentId: 1507971, ~/Articles/ArticleHandler.aspx, 4/16/2014 4:02:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 6 hours ago Sponsored by:
DOW 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASD 4,034.16 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/15/2014 3:59 PM
BIIB $285.49 Up +5.97 +2.14%
Biogen Idec CAPS Rating: ****
CTIC $3.05 Down -0.08 -2.56%
Cell Therapeutics,… CAPS Rating: *
PDLI $8.17 Up +0.04 +0.49%
PDL BioPharma CAPS Rating: ***
SPPI $6.70 Down -0.07 -1.03%
Spectrum Pharmaceu… CAPS Rating: ***

Advertisement